Travis Wilson

Travis Wilson joined Flagship Pioneering in 2024 as a Growth Partner helping to grow and scale several portfolio companies by working together with leaders throughout the ecosystem on long-term value creation strategy, financing, business development, partnerships, and organizational development.

Travis has more than 20 years of life sciences investing and executive experience. Previously he served in investing roles at private and growth equity firms. Prior to that, Travis was the President and CEO of Stealth BioTherapeutics (NASDAQ: MITO), a mitochondrial focused company developing a therapeutic platform to treat common and rare diseases. While CEO of Stealth Biotherapeutics, and for more than a decade, he was a member of the life sciences investment team for Morningside, a global venture and private equity firm. As an investor with Morningside, Travis was involved in several successful deals, including BioVex (acquired by Amgen), Aduro (merged with Chinook Therapeutics, NASDAQ: KDNY), Liquidia (NASDAQ: LQDA), Apellis (NASDAQ: APLS), and ACD (acquired by Bio-Techne).

Travis has also served as a Board director for nonclinical, late-stage clinical, and commercial life sciences companies, providing operational and management support across a broad spectrum of therapeutic areas, including orphan diseases, oncology, immunology, cardio-renal disorders, neurology, and ophthalmology. He has regularly spoken on life sciences investing and portfolio management, and is a long-time supporter of patient-advocacy groups including the American Cancer Society, United Mitochondrial Disease Foundation, and National Organization for Rare Disorders.

Travis received degrees in Chemical Engineering and Law, both from the University of Wisconsin.